Drug Combination Details
| General Information of the Combination (ID: C35866) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Lithium chloride Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Rhabdomyosarcoma
[ICD-11: 2B55]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RD | CVCL_1649 | Embryonal rhabdomyosarcoma | Homo sapiens | ||
| Rh30 | CVCL_0041 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. | |||||
